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Abstract
Aim: To compare the efficacy and safety of dinoprostone vaginal insert (DVI) alone versus DVI with adjunc-
tive sweeping of membranes (ASM) for induction of labor (IOL).
Methods: Single-center, prospective, randomized controlled trial; women with singleton term pregnancies,
cervical dilation ≥1 and <3 cm, intact membranes allocated to either DVI or DVI with ASM. The primary out-
come was vaginal delivery within 24 h of insertion. Secondary outcomes included mean time from insertion
to delivery, tachysystole, operative delivery for non-reassuring fetal status (NRFS), tocolytics, fetal outcomes,
pain information, and subject satisfaction.
Results: One hundred and four received DVI (Group 1) alone and 104 DVI with ASM (Group 2). The rate of
vaginal delivery within 24 h was 53% versus 56%, cesarean rate 8.7% versus 10.6% in Groups 1 and 2 respec-
tively. Although the duration of labor was similar in both groups, about 6% of women required additional
ripening with dinoprostone vaginal tablets in Group 2 compared to 11.5% in Group 1 (p-value = 0.2). The
frequency of hyperstimulation syndrome, failed induction, analgesic requirements, and fetal outcomes were
comparable. The majority (83%–86%) in either cohort were satisfied with their labor experience. Multivariate
logistic regression demonstrated a slightly better chance for vaginal delivery within 24 h (odds ratio
[OR] 1.22 [95% confidence interval, CI 0.65–2.29]; p-value 0.53] for DVI with ASM, although statistically
insignificant. Younger maternal age and multiparity (OR 10.36 [95% CI 4.88–23.67]; p-value <0.0001) contrib-
uted to successful IOL.
Conclusion: DVI with ASM is at least as efficacious as DVI for cervical ripening with no increase in morbid-
ity. Although DVI with ASM group less often needed additional dinoprostone tablets to complete the pro-
cess of IOL (p-value = 0.2), adjunctive sweeping has not been shown to have a significant impact on the
duration of labor or mode of delivery.
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Introduction
Induction of labor (IOL) is a common obstetric inter-
vention used globally in 20% to 30% of pregnancies.1–3
Artificial initiation of labor is offered to pregnant
women when the benefits of expeditious delivery in
terms of maternal and perinatal outcomes outweigh the
risks of continuing the pregnancy. Common indications
include prolonged pregnancy, prelabor rupture of the
membranes, fetal growth restriction, oligohydramnios,
pre-eclampsia, maternal medical conditions, and so
on. Besides, the ARRIVE trial has shown the benefits of
IOL at 39 weeks in low-risk nulliparous women com-
pared with expectant management.4
The physiological processes involved in the initia-
tion of labor are complex and the success of induction
is largely determined by the cervical status. Prosta-
glandins, naturally occurring hormone-like com-
pounds, facilitate cervical softening, thinning, and
dilation resulting in its ripening.5,6 They stimulate cer-
vical remodeling, as well as other processes such as
uterine contractions through different mechanisms.
Hence, when cervical ripening has not occurred natu-
rally before labor induction, prostaglandins have been
successfully used for ripening. Mechanical methods
used (e.g., membrane sweeping, or Foley or double-
balloon catheters or osmotic dilators) function in part
by promoting the local release of endogenous
prostaglandins.1,5,7
Dinoprostone is a synthetic preparation that is chemi-
cally identical to naturally occurring prostaglandin E2
(PGE2) while misoprostol, is an another synthetic pros-
taglandin E1 analogue.6 Dinoprostone is approved in
many countries as an endocervical gel, vaginal tablet,
and vaginal insert formulations. Dinoprostone vaginal
insert (DVI) is FDA approved and provides a low-dose,
controlled-release at 0.3 mg/h over 12–24 h. Its efficacy
and safety have been evaluated in numerous random-
ized trials. It has been proven to be superior to pla-
cebo8–10 and generally comparable to other
dinoprostone formulations or misoprostol.11–14 The opti-
mal method for ripening the cervix is still uncertain.
Stripping or sweeping the amniotic membranes is
commonly practiced to induce labor. Phospholipase
A2 activity and prostaglandin F2α (PGF2α) levels
increase significantly following membrane stripping.15
There is evidence that it increases the likelihood of
spontaneous labor within 48 h and reduces the inci-
dence of induction. A recent 2020 Cochrane review
update16,17 including 44 studies, reported supporting
data for 6940 women and their infants comparing
membrane sweeping to expectant management or
misoprostol or oxytocin. Guidelines generally recom-
mend women should be offered a vaginal examina-
tion for membrane sweeping before formal IOL.18–20
Previous research was mainly focused on the com-
parison of prostaglandin E2 inserts with other
mechanical methods such as Foley catheter, showing
differences in efficacy outcomes.21–23 Little is known
about the synergistic effects of prostaglandins and
mechanical methods such as slow-release vaginal
prostaglandin E2 inserts and membrane sweeping.
We believe that the adjunctive sweeping of mem-
branes (ASM) before DVI insertion will increase the
success rate of IOL and shorten the labor process.
Thus, it may improve the clinical performance of DVI
and patient satisfaction. We have conducted a pro-
spective, randomized controlled trial comparing the
efficacy and safety of DVI alone versus a combination
of DVI with adjunctive sweeping for term IOL.
Material and Methods
This prospective cohort study was conducted at a single
tertiary care medical center, KK Women’s & Children’s
Hospital, Singapore. Women over 21 years of age with a
term singleton pregnancy, requiring IOL at 37–42 weeks
with an unfavorable cervix (Bishop’s score <7, cervical
dilatation of ≥1 cm and <3 cm) were eligible for the
study. Prior cesarean delivery, history of uterine surgery,
sensitivity to dinoprostone, grand multiparity (≥5 previ-
ous deliveries), nonvertex presentation of the fetus, rup-
tured membranes, abnormal cardiotocography (CTG) or
suspected fetal compromise, abnormal uterine bleed dur-
ing pregnancy, contraindications to vaginal delivery
(e.g., active herpes, placenta previa), multiple gestations,
who require urgent delivery (may benefit from surgical
delivery) were exclusion criteria. Clinicians were
instructed to omit sweeping in outpatient clinics before
scheduling for IOL.
Planned IOL was performed at the Obstetric Moni-
toring Unit or delivery suite depending on the indica-
tion as per institutional protocol. An initial vaginal
examination was done to determine the modified
Bishop’s score. Patients with an unfavorable cervix
who consented to participate in the study were ran-
domized to one of two arms: (1) DVI or (2) DVI and
ASM. Block randomization of cases was done.
Women in Group 1 were treated with a slow-
release DVI (CERVIDIL® 10 mg Vaginal Delivery Sys-
tem; Ferring, UK), which was placed in the posterior
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vaginal fornix. Group 2 women had an adjunctive
cervical sweep prior to insertion which entailed pas-
sage of the examining finger through the cervix so
that it can be rotated against the wall of the uterus
beyond the internal cervical os, thereby stripping the
amnion away from the decidua. Electronic fetal moni-
toring was done for an hour after the insertion of DVI
and repeated 4–6 h later. The insert was left in place
for 24 h, or until active labor started or else there was
hyperstimulation or spontaneous rupture of mem-
branes. In both the groups, if the cervix was found to
be ≥3 cm dilated on follow-up examination,
amniotomy was performed and oxytocin augmenta-
tion was started when contractions or progress were
deemed inadequate. Continuous fetal monitoring by
CTG was started after amniotomy. Cases where
amniotomy was not possible after 24 h of DVI inser-
tion were considered failed IOL and were managed
with an additional trial of cervical ripening either
with dinoprostone vaginal tablet or mechanical ripen-
ing using a balloon catheter.
Data were collected on women’s characteristics,
admission examination, continuous monitoring of
uterine contractions, as well as subsequent labor man-
agement (e.g., oxytocin regimen and labor progres-
sion) and birth outcomes. After delivery, a member of
the study team interviewed the patients. Information
collected included patients’ views on pain felt during
the induction process, overall satisfaction, comments,
and whether they would recommend their mode of
induction to other women. A visual analog scale
(Wong-Baker Faces Pain Rating Scale) and satisfaction
chart were shown to the subjects during the verbal
survey to aid in the process.
Primary outcome: Successful IOL was defined as
vaginal delivery within 24 h of initiation by the induc-
tion agent.
Secondary outcomes: Comparison between two
study cohorts with respect to mean time from inser-
tion to delivery, tachysystole, need for oxytocin for
augmentation of labor, need for instrumental delivery
or cesarean section, need for analgesia, and patient
satisfaction.
Onset of labor was defined as regular painful con-
tractions (3 in 10 min) resulting in progressive efface-
ment and dilatation of the cervix.
Uterine hyperstimulation was diagnosed if contrac-
tion frequency exceeded 5 in 10 min or contractions
exceeded 2 min.24
Late decelerations, moderate and severe variable
decelerations, and bradycardia were considered
abnormalities on the fetal heart rate tracing. Factors
affecting successful labor induction were analyzed
separately.
All statistical analyses were conducted with “R”
software. The sample size was calculated to be
approximately 100 women in each group to achieve a
statistically 80% power (α 0.05) to show a 20% reduc-
tion in the meantime from insertion to delivery from
25.2 h in DVI alone group to 20.2 h in the DVI with
membrane sweeping group. The effect size of 20%
reduction is a hypothetical estimate that is expected
to be clinically meaningful to differentiate the two
methods. Chi-square test was used for categorical var-
iables. Student’s t-test and Mann–Whitney U test
were used for continuous variables comparing mean
and median, respectively. Categorical variables were
expressed as percentages and continuous variables as
mean  standard deviation or median with inter-
quartile range (IQR). Multivariate logistic regressions
were performed to assess the correlation between nor-
mal vaginal delivery within 24 h and risk factors.
p < 0.05 was considered to indicate statistical
significance.
The study was approved by the SingHealth Cen-
tralised Institutional Review Board and registered
with the ID number 2018/2338.
Results
During the study period, 1613 women presenting for
term IOL were contacted. A total of 208 women met
the inclusion criteria and were included in the study,
of them 104 underwent cervical ripening with a DVI
while the rest of 104 had adjunctive cervical sweeping
prior to insertion of DVI (Figure 1). The demographic
and obstetric characteristics of both cohorts are shown
in Table 1. Both groups were comparable with respect
to maternal age, race, pregestational BMI, parity, and
GA at induction. There were no differences in the
indications for IOL between them as well.
The primary efficacy outcome variable was delivery
within 24 h of insertion of the induction agent. Both
induction methods were equally effective in terms of
achieving vaginal delivery within 24 h of insertion.
Also, the number of women undergoing cesarean
section within 24 h of insertion was not significantly
different between the two groups. The time interval
from the insertion of DVI to the onset of regular uter-
ine contractions and the insertion-to-delivery interval
were not different between the groups (Table 2).
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There was no significant difference in the mode of
delivery between the two groups.
There were no differences between the two groups
regarding the frequency of uterine hyperstimulation, the
occurrence of abnormal fetal heart rate patterns during
the first stage of labor, Apgar scores, or umbilical artery
pH values. Likewise, oxytocin and analgesic require-
ments were similar in both groups. Twelve women
required additional dinoprostone vaginal tablets in
Group 1 compared to six in Group 2 (p-value = 0.2).
A total of 12 women in Group 1 experienced uter-
ine hyperstimulation (Table 3), of which, in 9 of these
women, it resolved immediately on removal of the
insert and/or administration of a tocolytic; a
β2-sympathomimetic drug (Terbutaline). Four women
required immediate instrumental or cesarean birth
within 1 h. Two newborns required observation in a
special care nursery. In Group 2, 14 women experi-
enced hyperstimulation syndrome. Five women
required removal of insert, in three of these women,
removal of the insert was sufficient to stop the uterine
hyperstimulation, and no tocolytic therapy was
required. In six cases, a tocolytic was necessary to end
the hyperstimulation. Three mothers required imme-
diate delivery for abnormal fetal heart rate patterns.
One woman induced for gestational diabetes mellitus
experienced uterine hyperstimulation associated with
an abnormal fetal heart rate pattern and tachysystole
abated after removal of insert and tocolytic. She had a
cesarean section 8 h later for non-reassuring fetal sta-
tus, the baby was under observation in the nursery
for 24 h without adverse outcome. Three women in
each cohort did not require any interventions.
Women from Group 2 who underwent membrane
sweeping before DVI insertion did report additional dis-
comfort or pain from the procedure compared to Group
1 (p-value = 0.03) but still, they did not require addi-
tional analgesics and the majority (83%) of participants
were satisfied with their labor experience and would
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FIGURE 1 Patient flowchart according to the CONSORT statement
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Factors that significantly increased the likelihood of
achieving the primary outcome of vaginal delivery
within 24 h were younger maternal age and
multiparity. DVI with adjunctive membrane sweeping
was associated with a slightly increased likelihood of
vaginal delivery (OR 1.22 [0.65–2.29] p = 0.5),
although not statistically significant (Table 4).
Discussion
“The spontaneous onset of labour is a robust and
effective mechanism which is preceded by the matu-
ration of several fetal systems and should be given
every opportunity to operate on its own. We should
only induce labour when we are sure that we can do
better”—Alec Turnbull, 1976.25 The successful IOL
and achieving vaginal delivery will reduce the per-
centage of cesarean births. Despite the availability of
numerous mechanical and pharmacological methods,
the best intervention still eludes us as outcomes may
vary according to maternal and obstetric characteris-
tics. The present study was undertaken to assess
whether the combination of the routine obstetric prac-
tice of sweeping the membranes and prostaglandin
E2 vaginal insert is superior to prostaglandin E2 with-
out sweeping the membranes to achieve vaginal
delivery within 24 h.
Sweeping of the amniotic membranes for inducing
labor was first documented by James Hamilton, in
England in 1810.26 Several studies have reported
that membrane sweeping is associated with higher
rates of spontaneous vaginal delivery, shorter
induction-to-delivery interval, reduced likelihood of
post-term pregnancy, and a decreased need for
IOL.15,16,27–29 A Cochrane review in 200516 demon-
strated that membrane sweeping does not increase
the risk of maternal and neonatal infection. The
“STRIP-G” study confirmed that stripping was a safe










30.4  5.35 31.0  5.12
Advanced maternal
age (≥35 years)
22 (21.2) 28 (26.9)
Chinese race 55 (52.9) 47 (45.2)
Malay 24 (23.1) 33 (31.7)
Indian 13 (12.5) 8 (7.69)
Others 12 (11.5) 16 (15.4)
Body mass index,
mean  SD
25.2  5.35 25.9  6.31
BMI ≥ 30 18 (17.3) 27 (26.0)
BMI ≥ 40 1 (0.962) 3 (2.88)
Nulliparous 64 (61.5) 62 (59.6)
Multiparous 40 (38.5) 42 (40.4)
GA at induction (weeks),
median (IQR)
39.2 (1.6) 39.3 (1.7)
Bishop score,
median (IQR)
4 (2) 4 (2)
Indications
Term 25 (24.0) 22 (21.2)
Gestational/pre-existing
diabetes
23 (22.1) 26 (25.0)
Post date 19 (18.3) 17 (16.3)
Macrosomia 17 (16.3) 12 (11.5)
Amniotic fluid index <6 9 (8.65) 11 (10.6)
Maternal request 5 (4.81) 6 (5.77)
Reduced fetal movement 3 (2.88) 10 (9.6)
Pre-eclampsia/
hypertension
3 (2.88) 5 (4.81)
Intrauterine growth
restriction
1 (0.962) 0 (0.0)
Advanced maternal age 1 (0.962) (0.0)
Note: Data presented as n (%). and Abbreviations: BMI, body
mass index; DVI, dinoprostone vaginal insert; GA, gestational
age; SD, standard deviation.
TABLE 2 Labor outcomes
Outcomes DVI only (n = 104) DVI with sweep (n = 104) p-value
Primary labor outcomes
Vaginal delivery within 12 h 20 (19.2) 16 (15.4) 0.58
Vaginal delivery within 24 h 55 (52.9) 59 (56.7) 0.67
Cesarean section within 24 h 9 (8.65) 11 (10.6) 0.81
Delivery after 24 h 40 (38.5) 34 (32.7) 0.46
Secondary labor outcomes
Duration: insertion to onset of labor (h)a 10.7 (10.9) 10.6 (9.2) 0.99
Duration: insertion to full dilatation (h)a 17.6 (13.6) 18.8 (10.8) 0.64
Duration: insertion to delivery (h)a 20.4 (16.2) 21.3 (14.8) 0.76
Duration: onset of labor to delivery (h)a 9.1 (8.1) 8.9 (8.3) 0.35
Need for oxytocin 50 (48.1) 61 (58.7) 0.16
Need for dinoprostone vaginal tablet 12 (11.5) 6 (5.8) 0.22
Note: Data presented as n (%).; Abbreviation: DVI, dinoprostone vaginal insert. and aData presented as median (IQR).
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procedure in women who were even found to be
carriers of Streptococcus agalactiae (Group B
Streptococcus).30
DVI (Cervidil®; Propess®), a retrievable vaginal
pessary—a controlled-release drug delivery device, is
approved in many countries worldwide for inducing
cervical ripening in patients at term prior to labor
induction. The effectiveness of DVI has been demon-
strated in a vast range of randomized clinical trials in
women at term.8–14 The insert is well tolerated, with
generally favorable maternal, fetal, and neonatal out-
comes. Sustained constant slow release of PGE2 from
the vaginal insert with or without prior sweep was an
important advantage of this induction method in
terms of controlling the labor and in particular rap-
idly reversing uterine hyperstimulation through easy
retrieval of the vaginal insert.
The present study demonstrated both DVI alone or
DVI with ASM are effective and safe for cervical rip-
ening with no increase in morbidity. Additional mem-
brane sweeping was expected to improve the chances
for vaginal delivery within 24 h by the release of
additional local endogenous prostaglandins, however
statistical significance and hence its clinical merits
could not be proven. There were no additional mater-
nal or fetal morbidities reported in either of the
cohorts. There were no significant additional reports
of uterine hyperstimulation or tachysystole with
adjunctive membrane sweeping. No additional emer-
gent instrumental or cesarean births were required in
Group 2 women with hyperstimulation confirming
the safety of the induction method.
TABLE 3 Perinatal outcomes and side effects profile
Outcomes DVI only (n = 104) DVI with sweep (n = 104) p-value
Birth weight (g), SD 3428.8  378.3 3164.2  380.6 0.11
5 min APGAR < 7 0 (0.0) 1 (0.9) 1
Cesarean section for NRFS 8 (7.7) 7 (6.7) 1
Failed induction 13 (12.5) 13 (12.5) 1
• Required dinoprostone vaginal tablet 9/13 (69.2) 6/13 (46.2) 0.5
• Cesarean section 9/13 (69.2) 9/13 (69.2) 1
• Instrumental delivery 4/13 (30.8) 0/13 0.13
• Normal vaginal delivery 0/13 4/13 (30.8) 0.13
Post-partum hemorrhage 1 (0.9) 0 (0.0) 1
Uterine rupture 0 (0.0) 0 (0.0) NA
Fever 25 (24.0) 23 (22.1) 0.87
Vomiting 7 (6.7) 5 (4.8) 0.77
Hyperstimulation syndrome 12 (11.5) 14 (13.5) 0.83
• Required removal of DVI only 2 (16.7) 3 (21.4) 1
• Required tocolysis only 2 (16.7) 6 (42.8) 0.31
• Required removal of DVI and tocolysis 5 (41.7) 2 (14.3) 0.51
• No intervention 3 (25) 3 (21.4) 1
• Required immediate delivery 4 (33.3) 3 (21.4) 0.81
• Cord pH ≤7.1 2/8 (25) 5/10 (50) 0.55
• Required SCN/NICU stay 2 (16.7) 3 (21.4) 1
Tachysystole 26 (25.0) 28 (26.9) 0.87
Required removal of DVI 18/26 (69.2) 18/28 (64.3)
Required tocolysis 1/26 (3.85)
Patient satisfaction
Pain scorea 1 (4) 2 (2) 0.03
Discomfort scorea 5 (3.3) 5 (4) 0.65
Recommend this method 86 (82.7) 83 (79.8) 0.72
Note: Data presented as n (%).; Abbreviations: DVI, dinoprostone vaginal insert; NICU, neonatal intensive care unit; NRFS, non-reassuring
fetal status; SCN, special care nursery; SD, standard deviation. and aData presented as median (IQR).
TABLE 4 Multivariate logistic regression for vaginal
delivery within 24 h
Factors ORs 95% CI p-value
Allocation 1.22 0.65–2.29 0.53
Maternal age 0.88 0.82–0.94 0.0003
Parity 10.36 4.88–23.67 <0.0001
Booking BMI 0.96 0.90–1.01 0.14
Birth weight 0.9 0.99–1 0.01
GA at delivery 1.16 0.82–1.65 0.39
Abbreviations: BMI, body mass index; CI, confidence interval;
ORS, odds ratios; GA, gestational age.
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The addition of sweeping did not compromise
patient satisfaction although labor was perceived as
more painful, there were no additional analgesic
requirements in Group 2. Measuring patient satisfac-
tion allowed patients to evaluate received services
and treatments. It also helps to identify possible prob-
lems and suggests ways of improving the quality of
care or interventions. There have been no randomized
studies so far reporting efficacy and safety of this
mechanical method, that is, membrane sweeping,
with DVI for term IOL. To our knowledge, this is the
first prospective randomized trial comparing DVI
alone and DVI with prior sweeping.
The strength of this study lies in its prospective,
randomized control design, enabling complete and
thorough data collection. Another important strength
of this study is being done at a single center where
the structured, detailed protocol for labor induction
with DVI was followed and all women were treated
similarly. This attenuates any biases related to differ-
ent management approaches.
Limitation of this study was that the patients and
clinicians were not blinded to the allocation of the
study groups because of the nature of the interven-
tion. This study was likely underpowered to evaluate
the benefits of the addition of sweeping to DVI for
IOL, future studies with larger cohorts are needed to
better assess these issues. Better results may be possi-
ble if ASM is performed and prostaglandin insert
(PGI) inserted 12 h later but such hypotheses need to
be tested in clinical trials.
Conclusion
Results of this randomized trial showed that both
DVI with membrane sweeping and DVI alone were
effective in the IOL. Adjunctive sweeping although
safe does not benefit in terms of achieving successful
vaginal delivery within 24 h earlier compared to DVI
alone. Patient satisfaction scores were comparable in
both groups.
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